Bildnachweis: Foto von ThisisEngineering auf Unsplash.
Drug development, medical technology, or digital health: few industries are as capital-intensive as the life sciences. Yet, knowing precisely when to submit which application can drastically reduce burn rates and effectively extend a start-up’s runway. This is a guide through the phases, pitfalls, and premier funding pools for biotech, medtech, and AI.
A look at the 2025 figures reveals why this guide is a matter of survival. At first glance, the balance sheet appears robust – boasting approximately EUR 1.79 billion in total financing – but appearances are deceptive. Strip away outliers like Tubulis’s record rounds or Qiagen’s massive credit facilities, and the reality is stark: venture capital for private, unlisted start-ups has plummeted by 34%. Private purse strings are tighter than they have been in years. Nevertheless, the sector is booming. The number of new ventures in medicine and life sciences surged by 46% in 2025 (driven by hubs like Bavaria). Moreover, 27% of these new players integrate AI, significantly raising the bar for technological sophistication. This is the conclusion of an analysis by the biotechnology industry association BIO Deutschland e. V. in cooperation with EY. The bottom line? Founders are battling a larger number of competitors for a smaller pool of private capital. In this climate, the only reliable variable to bridge the gap is the strategic utilisation of public funding. Here is the roadmap for smart money – from the petri dish to the exit.
Phase One: The Golden Era in the lab (pre-seed)
Paradoxically, the most valuable phase is when the company does not yet exist. For teams still anchored at a university or research institution, the mantra applies: do not incorporate too early! For red biotechnology, the BMBF’s GO-Bio funding pipeline is widely considered the ‘holy grail’. Starting with GO-Bio initial for early-stage validation and extending to advanced follow-up programs like GO-Bio next, the pipeline is explicitly tailored to the prohibitive costs of drug development. It allows successful applicants to secure massive funding — eventually reaching into the millions — enabling teams to significantly de-risk their scientific findings before venture capital investors enter the picture. Meanwhile, for deeptech sectors such as medtech, diagnostics, and platforms, the exist-Forschungstransfer is the industry standard. This programme finances four salaries and covers up to EUR 250,000 in material costs, all at a 100% funding rate. The fatal flaw: anyone who visits a notary for incorporation before the grant decision arrives loses everything. The GmbH must not yet formally exist. Furthermore, IP/patents must be clearly regulated with the university – a ‘handshake deal’ with the professor will not satisfy the project management agency.
Phase Two: Jumping in at the deep end (seed)
Once the GmbH is founded, the battle for liquidity begins. This is the hour of state-level programmes. Whether Start-up BW Pre-Seed or Berlin’s GründungsBonus – federal states often offer convertible loans or grants to bridge the gap. Simultaneously, business angels must be brought on board. The crucial argument here is the INVEST-Zuschuss für Wagniskapital. The state reimburses the angel 15% of their investment sum (minimum EUR 10,000 investment), tax-free, making the risk much more palatable for private investors. Note: check the daily updated funding rate, as it frequently fluctuates between 15% and 25% due to political shifts. If angels are insufficient, the High-Tech Gründerfonds (HTGF) comes into play. It acts as a bridge between state aid and private venture capital. With a dedicated life sciences team, the HTGF often acts as the lead investor. It is more patient than private venture capitalists and accepts the longer development cycles of biotech. Note: ‘family and friends’ funding does not work for INVEST. Investors must not be related to founders, and money must flow via a capital increase; private share purchases
are excluded.
Phase Three: The fork in the road – biotech versus medtech
When development becomes truly expensive, the wheat separates from the chaff. For major R&D projects, founders must choose between two primary instruments: Zentrales Innovationsprogramm Mittelstand (ZIM) and KMU-innovativ. Unfortunately, many choose the wrong one based on a fundamental misunderstanding of how risk is evaluated. If you are an engineer building a new catheter or sensor, your home turf is ZIM, which explicitly favours technical risks and engineering solutions. However, if you are a biologist researching active pharmaceutical ingredients, you must avoid ZIM at all costs. The programme often views the risk of ‘molecule binding failure’ as a biological risk rather than a technical one, making rejection highly likely. For these drug development projects, KMU-innovativ (Biomedizin) is the correct venue. Finally, there is the coder developing digital health solutions, such as an AI for cancer detection. While medically valuable, the underlying technology is fundamentally computer science. Instead of the biomedicine track, these start-ups fare much better in KMU-innovativ ‘IKT’. Here, the reviewers evaluate the algorithmic innovation itself, which massively increases the chances of securing funding for digital health start-ups.
Phase Four: The ‘Champions League’ (scale-up)
When the product is validated and scaling is imminent, eyes turn to Brussels for the ‘Champions League’ of funding. The EIC Accelerator is Europe’s most prestigious instrument, offering up to EUR 2.5 million as a grant and up to EUR 10 million in equity, with even higher amounts available under the specialized Step Scale Up call. However, you must navigate a paradoxical needle’s eye: the strict requirement of ‘non-bankability.’ You must prove that private venture capitalists still shy away due to the high risk– a true ‘market failure’ – while simultaneously demonstrating that your technology has the potential to radically alter global markets.
The ‘Death Zone’: Administrative knockout criteria
Yet, reaching this stage means nothing if you stumble into the administrative ‘death zone.’ Even Nobel Prize-worthy technology will fail instantly if basic formalities are ignored. The first absolute knockout is a premature project start. If you order reagents or sign a CRO contract before the official submission, the entire project becomes ineligible. You must wait for the confirmation letter or strictly use non-binding ‘letters of intent’ to prepare your operations. Another lethal bureaucratic trap is the ‘undertaking in difficulty’ (UiD) designation. If your start-up is older than three years and has consumed more than half of its subscribed capital through accumulated losses, you are categorically blocked from major national programmes like ZIM and KMU-innovativ. Finally, founders frequently underestimate the solvency trap. Programmes such as ZIM reimburse retroactively, meaning your matching funds – the required own contribution – must be verifiably liquid and visible on your balance sheet at the exact time of application.
The reality check: 2026 calls
Fund availability remains volatile. Due to fiscal consolidation, programmes frequently face pauses or freezes, and processing times may drag as agencies await new funding tranches. While instruments like ZIM or ‘exist’ accept rolling submissions, major funding pools operate with rigid cut-off dates. Missing these can cost you up to six months of runway, as is the case with KMU-innovativ (Biomedizin and ICT), which enforces strict deadlines on 15 April and 15 October 2026. For GO-Bio initial (BMBF), founders should prepare to apply from autumn 2026 onwards. Fortunately, the EU’s EIC Accelerator has moved to a more flexible schedule, now featuring six stage two cut-offs per year (e.g. 6 May, 8 July, 2 September, and 4 November). The ultimate strategic takeaway: never rely entirely on a punctual project start for liquidity. Build a three-to-six-month buffer, check agency websites daily, and remember that you have no legal claim to funding until you hold the written grant decision.
